Low levels of plasma vitamin D have been implicated as a possible risk factor for both prostate cancer incidence and advanced disease, and recent phase II trials suggest that vitamin D supplementation might delay progression of prostate cancer. Common polymorphisms in the vitamin D receptor (VDR) are associated with VDR activity and are therefore potentially useful proxies for assessing whether vitamin D is causally related to advanced prostate cancer. We genotyped five well-known VDR polymorphisms in 1,604 men with prostate cancer from the Prostate Testing for Cancer and Treatment study. Our aim was to examine the association between VDR polymorphisms and cancer stage (localized versus advanced) as well as cancer grade (Gleason score <7 versus ≥7). Moreover, we also carried out a systematic review and meta-analysis of 13 similar studies. As a result of our meta-analysis, we revealed three polymorphisms, BsmI, ApaI, and TaqI, associated with high Gleason score with an overall summary odds ratios (95% confidence intervals) of 1.12 (1.00-1.25; bb versus BB + Bb), 1.25 (1.02-1.53; aa versus AA + Aa), and 0.82 (0.69-0.98; Tt + tt versus TT), respectively. The haplotype analysis revealed that the BsmI (B)-ApaI (A)-TaqI (t) participants compared with BsmI (b)-ApaI (a)-TaqI (T) individuals were less likely to have high Gleason scores (odds ratio, 0.84; 95% confidence interval, 0.71-1.00; P unadjusted = 0.050; P adjusted = 0.014). Our finding provides some support for the hypothesis that low levels of vitamin D may increase the risk of prostate cancer progression. (Cancer Epidemiol Biomarkers Prev 2009;18(11):2874-81) 
Introduction
Low levels of vitamin D were first implicated as a possible risk factor for prostate cancer in a landmark study by Apperly (1) who reported a positive correlation between prostate cancer mortality and reduced UV radiation exposure. Since that study, evidence from several sources has implicated low levels of vitamin D as a risk factor for prostate cancer development and disease severity at diagnosis, the latter being a marker of cancer aggressiveness and progression. In vitro experiments have shown that the presence of vitamin D can inhibit growth of prostate cancer cells (2) (3) (4) . However, prospective cohort studies of the association of prediagnosis vitamin D status with prostate cancer risk have found inconsistent associations, with inverse (5, 6), null (7) (8) (9) (10) (11) , "U"-shaped (12) , and even positive associations with aggressive cancer being reported (13, 14) . Most of these studies have small sample sizes and it has been suggested that many that reported null associations may have been underpowered to detect an inverse association (13) . Furthermore, the hypothesized effect of vitamin D on prostate cancer (primarily thought to be via inhibition of cancer cell growth) may mean that it is more likely that low levels of vitamin D are associated with how rapidly the disease progresses rather than as a primary etiologic risk factor for disease occurrence. With the pharmaceutical industry attempting to develop high-dose vitamin D drugs with limited sideeffects for the treatment of men with prostate cancer (15, 16) , it is important to examine the extent to which variation in vitamin D level or activity is likely to be related to disease severity and progression.
Vitamin D is initially metabolized to the intermediate compound 25 -hydroxyvitamin D in the liver and then subsequently binds to intracellular receptors, which regulate gene expression (17) . The vitamin D receptor (VDR) is an important regulator of the vitamin D pathway, which involves the conversion of serum 25-hydroxyvitamin D into the active hormone, 1,25-dihydroxyvitamin D (18) . There are five important common polymorphisms within the VDR gene region that are likely to exert functional effects on VDR expression. These polymorphisms are located in three linkage disequilibrium (LD) blocks: Cdx2, located in the promoter region upstream of exon 1, affects the binding ability of VDR and subsequent VDR transcriptional activity (19) ; FokI, located in the translation start of exon 2, produces a shorter protein with greater transcriptional activity (20) ; the three other variants, BsmI (intron 8), ApaI (intron 8), and TaqI (exon 9), are all located in one LD block, which is thought to contain other variants at 3′-untranslated region of the VDR gene that may influence VDR expression by altering the mRNA stability. Thus, these three LD blocks within the VDR are likely to have independent effects on vitamin D metabolism and hence levels or activity (17, 21) .
Because genetic variants are unrelated to the many environmental characteristics that tend to confound traditional risk factor-disease association studies (22, 23) , it has been suggested that genetic variants with robust associations with modifiable risk factors (in this case, circulating vitamin D) could be used as proxies to determine the unconfounded and unbiased effect of such risk factors on disease outcome (here, prostate cancer stage/grade at diagnosis). To date, several studies have examined the association between VDR polymorphisms and advanced prostate cancer. However, the results from those studies are inconsistent and inconclusive, with most studies being of small sample size (the majority including <200 men with prostate cancer; refs. 13, [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] .
In the present study, we undertook an analysis of VDR genetic variants in 1,604 prostate cancer patients who were identified prospectively through population-based PSA testing and had the clinical status of their cancer determined at the time of diagnosis. We then completed a systematic review of all published studies of the association of VDR genetic variants with advanced prostate cancer, and in a meta-analysis, we combined our results with those from the systematic review to estimate the overall association between VDR variants and prostate cancer stage/grade at diagnosis.
Participants and Method
Study Participants. Participants in this study were selected from the Prostate Testing for Cancer and Treatment (ProtecT) study (35) , which is a randomized controlled trial taking place in nine regions of the United Kingdom with the aim of evaluating the efficacy, costeffectiveness, and acceptability of treatments for localized prostate cancer. Men, without known prostate cancer, aged 50 to 69 years were invited to attend a nurse-led prostate-check clinic and have a prostate-specific antigen (PSA) test. Participants with a single raised PSA level over 3.0 ng/mL were invited to attend the center's urology department for digital rectal examination, repeat PSA test, (36) . Patients with cancer stage T 1 or T 2 were defined as having localized cancer, while individuals with a cancer stage of ≥T 3 were defined as advanced cases (Table 1) . Cancer grade was defined as lower grade with Gleason score of 1 to 6 and higher grade with a Gleason score ≥7. Of the total number of cancer cases we genotyped, 99.8% with cancer stage and/or grade information were included in this study.
DNA Extraction and Genotyping. Five VDR variants were genotyped in 1,604 prostate cancer cases as part of a genetic association study examining the effect of 70 diet/ nutrition relevant single nucleotide polymorphisms on prostate cancer risk. DNA was extracted by Tepnel 7 at the University of Sheffield, and genotyping was undertaken by KBioscience, 8 who use their own form of competitive allele-specific PCR (KASPar) and Taqman, for single nucleotide polymorphism analysis. Samples with >10% genotype failure (7 single nucleotide polymorphisms) were defined as having poor DNA quality (2.6%) and dropped from further analysis. Genotyping was repeated in 10% of the study samples (with independent assessment), and for 99.98% of those samples, there was exact agreement between the two. Based on standard nomenclature, genotypes for the four VDR variants, FokI (rs10735810), BsmI (rs1544410), ApaI (rs7975232), and TaqI (rs731236), were reported using lowercase and uppercase letters to reflect the presence or absence of a restriction site, which is consistent with the literature (FokI: T-f and C-F; BsmI: G-b and A-B; ApaI: T-A and G-a; and TaqI: T-T and C-t). The genotypes for Cxd2 (rs11568820) were labeled by their nucleotide bases.
Statistical Analysis. Hardy-Weinberg equilibrium of genotype frequencies among participants was tested using the Pearson χ 2 test. Genotypic effect was assessed by using information from the systematic review to inform the genetic models in our primary study, but we also tested alternative models. One-way ANOVA was used for testing mean differences among genotypes for quantitative variables, such as age, body mass index, and PSA level, whereas χ 2 tests were used for ordered categorical variables such as smoking status (current smoker, ever smoker, and nonsmoker), social class status (professional, intermediate, and manual), and weekly physical activity sessions (none, 1-2 times, 3-4 times, and ≥5 times). Logistic regression models were used for assessing genotype associations with prostate cancer stage/grade. Participants' characteristics associated with prostate cancer stage/grade were assessed using t and χ 2 tests. Statistical tests were two-sided and carried out in Stata statistical software (version 10). Pairwise LD (D′) between single nucleotide polymorphisms was calculated using Haploview (37) and haplotype analysis was done using the haplo.stats package (38) in R. Odds ratios (OR) were calculated by using the most common haplotype as baseline reference. Logistic regression was used to determine the association between VDR haplotypes and prostate cancer stage/grade. Systematic Review and Meta-analysis. Articles published or available online before August 14, 2008 were retrieved from Medline, 9 ISI Web of Knowledge, 10 and Embase 11 using the search terms: "prostate cancer" or "prostatic neoplasms (MeSH keywords)" in combination with "vitamin D (MeSH keywords)" and "vitamin D receptor" or "VDR." Relevant articles cited in the bibliography of retrieved articles were also included. Selection of articles was done by two independent researchers (L.C. and W.Y.) to avoid bias. Our inclusion criteria were that the article had to report an association between any genetic variant in VDR and advanced prostate cancer (advanced versus localized). Studies that only used PSA level or bone scan to assess prostate cancer stage were excluded, as these are not valid or reliable methods for cancer staging (n = 2 studies; refs. 39, 40) . No articles were excluded based on language. Where studies appeared to fulfill our inclusion criteria but did not include all the information necessary for inclusion in our meta-analyses, the corresponding authors were contacted for relevant data. For studies that published more than once, only the most recent publication was included.
Meta-analysis was carried out using data from all articles that determined the association between genetic variants in the VDR gene and prostate cancer progression by comparing advanced cancer patients to individuals with localized cancer. Genotype distributions in advanced and localized cases were retrieved from publications. Unadjusted allelic ORs were calculated for all VDR polymorphisms. Different systems for determining whether an individual had localized or advanced prostate cancer were used in the retrieved articles. Articles that reported results based on the Jewett-Whitmore system were converted into TNM system using the following conversion: T 1a -A1; T 1b -A2; T 1c -B0; T 2a -B1; T 2b -B2; T 3a-b -C1; T 3c -C2-3; N + -D1 based on "Clinical Staging of Prostate Cancer." 12 Gleason score and relative tumor behavior was converted to cancer grade according to Huang et al. (34) . Where possible, we divided studies into two groups depending on whether they used Gleason score or TNM staging system and performed two fixed-effects meta-analyses to calculate summary OR estimates for these two methods of tumor evaluation.
We carried out a test for heterogeneity using I 2 and tested for small study bias using the Egger (41) and Begg (42) tests. Our results from ProtecT were also included in the meta-analysis.
Results
Genetic Association Analysis. Five VDR genetic variants, Cdx2, FokI, BsmI, ApaI, and TaqI, were genotyped and 43 participants who are not of European origin were excluded. Finally, 1,561 European origin men with prostate cancer that had been clinically staged or graded were included in the analysis. All participants had at least one successfully genotyped VDR polymorphism. Participants' baseline characteristics are presented by cancer stage/ grade in Table 2 . The mean age of participants in the study was 62.5 years and participants with advanced cancer were older than patients with localized cancer. Mean PSA level and the percentage of current smokers were also higher in advanced cancer patients (Table 2) .
Because genetic variants are randomly allocated at gamete formation, we expected no association between VDR genotypes and participants baseline characteristics. Consistent with our expectations, there was no association between VDR genetic variants and any of the baseline characteristics in Table 2 (all P values > 0.05; full results available from authors on request). Because none of these characteristics are associated with genotype (our exposure), they could not confound its association with cancer stage/grade. However, in all our association analyses, we present unadjusted and adjusted P values, with the latter adjusted for characteristics (age, PSA, and smoking), which are strongly associated with cancer status. This improves statistical efficiency in analyses and is equivalent to adjustment for baseline characteristics in randomized controlled trials.
Pearson χ 2 tests found that the FokI genotype was slightly out of Hardy-Weinberg equilibrium in our controls (P = 0.02), but no disequilibrium was found for other variants (BsmI: P = 0.79; ApaI: P = 0.33; TaqI: P = 0.92; Cdx2: P = 0.09). Table 3 displays the genotype counts for each VDR variant stratified according to disease status. Based on previous research collected by systematic review, we fitted an additive model to Cdx2, a dominant model to FokI and TaqI, and a recessive model to ApaI and BsmI. No VDR variant was associated with tumor stage. By contrast, all variants, except Cdx2, were associated with cancer grade accessed by Gleason score (Table 3) .
Strong LD exists between the genetic loci, BsmI, ApaI, and TaqI (BsmI and ApaI D′ = 1, R 2 = 0.58; ApaI and TaqI D′ = 0.99, R 2 = 0.58; BsmI and TaqI D′ = 0.98, R 2 = 0.96) but not with the loci Cdx2 or FokI (Fig. 1) . Table 4 presents the result of a haplotype analysis using the BsmI, ApaI, and TaqI loci. There was a weak association between the B-A-t haplotype and Gleason score [OR, 0.84; 95% confidence interval (95% CI), 0.71-1.00; P unadjusted = 0.050; Systematic Review and Meta-analysis. Figure 2 shows the flow of articles identified and finally included in our meta-analysis. Our systematic search identified 747 articles that were potentially relevant. However, only 17 of these examined the relationship between VDR polymorphisms and prostate cancer stage/grade. Of these 17 articles, 2 were excluded because they used PSA or bone scan only to stage prostate cancer. Of the remaining 15, after contact with authors, we were able to obtain relevant data to include 12 in our meta-analyses (together with our own results). Table 5 summarizes the studies. Most of the studies are small, with <200 participants. The one exception is a recent study with similar numbers to our primary analyses: 1,034 men assayed for BsmI and 1,010 men genotyped for FokI (13) . No association was detected between VDR polymorphisms and prostate cancer disease status (assessed by either Gleason grade or TNM stage) in that study.
In addition to our systematic search for published VDR advanced prostate cancer association studies, we also searched the currently available whole-genome association databases of prostate cancer (as of August 2008). That search showed that BsmI is the only polymorphism included in the current genome-wide chips. Data from a genome-wide association study (43) 13 has also been included in our meta-analysis.
A fixed-effects meta-analysis was done on four genetic variants, FokI (n = 5 studies contributing), ApaI (n = 5 studies contributing), BsmI (n = 9 studies contributing), and TaqI (n = 9 studies contributing), using Gleason score or TNM stage. Only one other study (in addition to ours) had examined the association of Cdx-2 variant with advanced prostate cancer; therefore, we did not complete a meta-analysis for that variant. Figure 3 shows the results of the meta-analyses for these four variants with Gleason score and prostate cancer stage. ApaI aa homozygotes were more likely to have a high cancer grade compared with ApaI-A allele carriers (AA and Aa; OR, 1.25; 95% CI, 1.02-1.53; P = 0.034; Fig. 3C ). The same effect has been found at the BsmI locus. Patients with two copies of the BsmI-b allele are at high risk of advanced cancer compared with BsmI-B carriers (OR, 1.11; 95% CI, 1.00-1.25; P = 0.079; Fig. 3B ). In contrast, patients with TaqI-t allele are at low risk of high Gleason score compared with TT carriers (OR, 0.82; 95% CI, 0.69-0.98; P = 0.03; Fig. 3D ). There was no strong evidence that the FokI polymorphism affected prostate cancer grade (Fig. 3A) . None of the variants were associated with cancer stage in these meta-analyses (Fig. 3) . Heterogeneity between studies in these different meta-analyses varied, with I 2 between 0% and 50.7%. Given these relatively low levels of between study heterogeneity, we did not conduct further metaregression analyses. An Egger test (41) and a Begg test (42) found no strong evidence of small study bias (all P values > 0.05).
Discussion
We carried out a genetic association study and metaanalysis of genetic variants in VDR and prostate cancer stage and/or grade at diagnosis. We found no consistent association of genetic variation in the VDR with cancer stage. However, there was an association between BsmI, ApaI, and TaqI genotypes and prostate cancer grade in both the ProtecT study and a meta-analysis of 13 studies published to date. The overall summary ORs showed that ApaI-a and BsmI-b increased the risk of a high cancer A study of 599 healthy men reported that those with the bb genotype at the BsmI locus had, on average, 2.3 pg/mL lower levels of 1,25-dihydroxyvitamin D compared with BB carriers (44) . If we assume that this association is causal (as our biological understanding of VDR would suggest), the summary OR of 1.12 from the meta-analysis of BsmI locus would be equivalent to an OR for advanced prostate cancer at diagnosis of 1.63 for a 10 pg/mL reduction of plasma 1,25-dihydroxyvitamin D. However, this is an over simplistic calculation given that VDR is not only involved in the metabolism of vitamin D but also is a nuclear receptor and a transcription factor, which mediates the biological functions of vitamin D (45) . Changes in VDR may therefore also have direct effects on vitamin D signaling and downstream effects on gene expression, which will in turn control cell proliferation. Our results provide some support for the hypothesis that plasma vitamin D level is an important factor in prostate cancer progression. This study represents a potentially important public health finding, as it suggests that oral vitamin supplementation (1,25-dihydroxyvitamin D) may help to prevent prostate cancer progression (15, 16) . However, randomized controlled trial evidence is ultimately required to confirm the effectiveness of vitamin D supplementation in men with prostate cancer. Our results support the importance of funding for such trials.
An important finding from our study and others identified in our systematic review was that associations of VDR with prostate cancer status were only consistently found for cancer Gleason grade and were not found for TNM stage. Both Gleason score and TNM are accepted as valid and reliable measures of assessing the aggressiveness and extent of prostate cancer and for predicting pathologic characteristics (46) . However, Gleason score was found to have higher predictive accuracy for biochemical recurrence compared with TNM staging system in a study of 971 advanced prostate cancer patients (47) . In our study, we found little overlap between advanced prostate cancer cases defined by these two methods (see Table 1 ). Only 19.4% of patients with Gleason score ≥7 have cancer stage ≥T 2c , whereas 72.2% of patients at stage ≥T 2c have Gleason score ≥7. A similar situation also occurs in other studies in our systematic review, suggesting that Gleason score may be a more sensitive measure of aggressive prostate cancer than TNM stage (14, 32, 48) . However, it is important to recognize that complete pathologic staging was not available in the majority of our cases and that histologic evaluation of Gleason scores is well known to be subject to variability, with both these factors potentially confounding the lack of correlation shown in our study.
Study Limitations. As with all genetic association studies, population admixture may have biased our findings. This may be particularly important here because prostate cancer prevalence varies with ancestry (49) as does VDR genotype (Table 5) . However, only British individuals of European origin were included in our analysis and there was no difference in genotype distribution across the centers that recruited men for the study. Despite being from different populations, there was little evidence of between-study heterogeneity in the associations assessed in our meta-analysis. All of the men with prostate cancer in this study were identified through a population-based PSA testing protocol (no one had been diagnosed with prostate cancer at recruitment); therefore, survivor bias is unlikely to have affected our results. This is supported by the fact that mean age did not differ by genotype for any of the VDR variants.
The meta-analysis combined studies from diverse populations, although the recent larger studies, such as Li et al. (13) and CGEMS (43) , are based on American Caucasians. Considering the small effect of VDR variants, population diversity and small sample size could reduce the power of the meta-analysis to reveal causal associations and our results would benefit from further replication in other large studies.
To conclude, our finding of associations between genetic variants in VDR and advanced prostate cancer at diagnosis provides some support for the hypothesis that low levels of vitamin D may increase the risk of prostate cancer progression. Further large studies that replicate these findings are needed to confirm this hypothesis.
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